Table 1.
Characteristics of patients with non‐small‐cell lung cancer treated with salazosulfapyridine in combination with cisplatin and pemetrexed (n = 15)
| Characteristics | No. of patients (n = 15) |
|---|---|
| Age, years | |
| Median | 66 |
| Range | 42–74 |
| Sex, n (%) | |
| Male | 10 (67) |
| Female | 5 (33) |
| ECOG performance status, n (%) | |
| 0 | 6 (40) |
| 1 | 9 (60) |
| Clinical stage, n (%) | |
| IIIB | 1 (7) |
| IV | 14 (93) |
| Histology, n (%) | |
| Adenocarcinoma | 15 (100) |
| Smoking status, n (%) | |
| Never smoked | 7 (47) |
| Ex‐smoker | 5 (33) |
| Current smoker | 3 (20) |
| Gene mutation status, n (%) | |
| None | 9 (60) |
| EGFR L858R | 3 (20) |
| EGFR Ex19del | 2 (13) |
| EML4‐ALK | 1 (7) |
| Prior treatment, n (%) | |
| None | 9 (60) |
| Gefitinib | 4 (27) |
| Afatinib | 1 (7) |
| Crizotinib and alectinib | 1 (7) |